WO2011058374A1 - Drug combination with theobromine and its use in therapy - Google Patents
Drug combination with theobromine and its use in therapy Download PDFInfo
- Publication number
- WO2011058374A1 WO2011058374A1 PCT/GB2010/051896 GB2010051896W WO2011058374A1 WO 2011058374 A1 WO2011058374 A1 WO 2011058374A1 GB 2010051896 W GB2010051896 W GB 2010051896W WO 2011058374 A1 WO2011058374 A1 WO 2011058374A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- theobromine
- opiate
- therapy
- codeine
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to a drug combination, its composition and its use in the therapy of cough.
- Cough is a protective reflex. Persistent cough can be distressing. Over- the-counter remedies are available but their effectiveness is doubtful.
- WO98/42322 discloses the use of theobromine for the treatment of cough, to be given orally.
- Codeine is an example of one such drug, and it is widely used as an antitussive. However due to the addictive properties of codeine and other opiates, there is a need for replacement cough therapies. Also, as recent evidence suggest, the therapeutic index for certain patient populations is very low.
- the invention is based at least in part on data showing a synergistic antitussive effect for theobromine combined with the opiate drug, codeine, in a citric acid-induced cough model.
- the data show that when theobromine is combined with codeine, the effect is surprisingly potent and greater than the sum of the individual drugs, revealing that the combination has a substantially improved effect.
- One advantage of lowering the minimum effective dose of codeine is that there is less chance of codeine overdose, as described above.
- an agent comprises theobromine and an opiate, as a combined preparation for simultaneous, sequential or separate use in therapy.
- Figure 1 shows the effect of theobromine, and a combination of theobromine and codeine, on citric acid-induced cough in guinea-pig.
- opioid describes any of the narcotic opioid alkaloids found as natural products in the opium poppy plant, as well as many chemical derivatives of such alkaloids.
- opioid describes a defined class of drugs, and will be understood by the person skilled in the art.
- any suitable form of theobromine can be chosen. These include salts, prodrugs and active metabolites.
- Theobromine may also be in the form of cocoa or chocolate. Suitable dose ranges for theobromine are known in the art, although the synergistic effect of the combination means that the effective dose may be reduced.
- the opiate may be used in an amount that is already known for its use, although combination according to this invention means that a reduced dose may be effective.
- the dose of the opiate that is administered with the theobromine will of course depend on the usual factors, including its potency, but is preferably at least 0.1 , e.g. at least 5, and may be up to 30 mg/kg/day.
- the opiate is preferably selected from codeine, morphine, diamorphine, thebaine, papaverine, noscapine, oripavine, fentanyl, alphamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanyl, propoxyphene, oxymorphone, oxycodone, hydromorphone, pethidine, dihydrocodeine, buprenorphine, etorphine, ethylmorphine, loperamide and hydrocodone, pentazocine and tramadol, tipepidine and noscapine.
- Codeine is the most preferred opiate drug , e.g. at a dose of 3 mg/kg/day.
- the compounds of the invention may be administered by any available route, such as via the oral, inhaled, intranasal, sublingual, intravenous, rectal and vaginal routes.
- the oral route is the preferred route of administration.
- the compounds of the invention are preferably as combinations to be administered orally, for example as tables, troches, lozenges, aqueous or oral suspensions, dispersible powders or granules.
- Preferred pharmaceutical compositions of the invention are tablets and capsules.
- Liquid dispersions for oral administration may be syrups, emulsions and suspensions. More preferably, the pharmaceutical composition of the combination is a pressed tablet or capsule with conventional excipients, examples of which are given below.
- compositions of the combination intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the combined active ingredients in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example starch gelatin, acacia, microcrystalline cellulose or polyvinyl pyrrolidone; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Aqueous suspensions contain the combined active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids, for example polyoxyethylene sorbitan monooleate.
- suspending agents for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum
- the aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p- hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl or n-propyl p- hydroxybenzoate
- colouring agents for example ethyl or n-propyl p- hydroxybenzoate
- flavouring agents such as sucrose or saccharin.
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, polyoxyethylene hydrogenated castor oil, fatty acids such as oleic acid, or in a mineral oil such as liquid paraffin or in other surfactants or detergents.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents, such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the combined active ingredients in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable sweetening, flavouring and colouring agents may also be present.
- the combined pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin, or mixtures of these.
- Suitable emulsifying agents may be naturally occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
- Suspensions and emulsions may contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- a carrier for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- theobromine in combination with an antitussive drug is to be administered via the oral route.
- Combined compositions according to the invention may be produced using conventional formulation techniques.
- spray-drying may be used to produce microparticles comprising the active agent dispersed or suspended within a material that provides the controlled release properties.
- the process of milling may also be used to formulate the therapeutic composition.
- the manufacture of fine particles by milling can be achieved using conventional techniques.
- milling is used herein to refer to any mechanical process which applies sufficient force to the particles of active material to break or grind the particles down into fine particles.
- Various milling devices and conditions are suitable for use in the production of the compositions of the invention.
- the selection of appropriate milling conditions, for example, intensity of milling and duration, to provide the required degree of force, will be within the ability of the skilled person.
- Ball milling is a preferred method.
- a high pressure homogeniser may be used, in which a fluid containing the particles is forced through a valve at high pressure, producing conditions of high shear and turbulence.
- Suitable homogenisers include the EmulsiFlex high pressure homogeniser, the Niro Soavi high pressure homogeniser and the Microfluidics Microfluidiser.
- the milling process can be used to provide the microparticles with mass median aerodynamic diameters as specified above. If hygroscopic, the active agent may be milled with a hydrophobic material, as stated above.
- the microparticles produced by the milling step can then be formulated with an additional excipient.
- an additional excipient This may be achieved by a spray- drying process, e.g. co-spray-drying.
- the particles are suspended in a solvent and co-spray-dried with a solution or suspension of the additional excipient.
- Preferred additional excipients include polysaccharides. Additional pharmaceutically effective excipients may also be used.
- Compositions of the combination intended for inhaled, topical, intranasal, intravenous, sublingual, rectal and vaginal use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
- Therapy according to the invention may be conducted in generally known manner, depending on various factors, such as the sex, age or condition of the patient, and the existence or otherwise of one or more concomitant therapies.
- the patient population may be important.
- the present invention is based at least in part on the following study. Study
- Cough was induced in guinea-pigs by the use of citric acid.
- One group of guinea-pigs was administered 7 mg/kg of theobromine, and two groups were administered theobromine in combination with 8 or 16 mg/kg of codeine.
- a fourth group was given codeine and, as a control, a fifth group receiv ed only vehicle. Administration was via the oral route.
Abstract
Description
Claims
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080051628.4A CN102740853B (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
UAA201207163A UA105940C2 (en) | 2009-11-13 | 2010-11-12 | Drug formulation with theobromine and opiate for treatment of cough |
CA2780704A CA2780704C (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
NZ599957A NZ599957A (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
MX2012005538A MX2012005538A (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy. |
EP10778715A EP2498776A1 (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
JP2012538416A JP2013510842A (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
RU2012124063/15A RU2587329C2 (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and use thereof in treatment |
BR112012011224A BR112012011224A2 (en) | 2009-11-13 | 2010-11-12 | theobromine and agent combined with an antitussive opioid and its therapeutic use |
AU2010317668A AU2010317668C1 (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
US13/446,217 US20120252824A1 (en) | 2009-06-16 | 2012-04-13 | Drug Combinations and Uses in Treating a Coughing Condition |
ECSP12011893 ECSP12011893A (en) | 2009-11-13 | 2012-05-11 | COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY |
ECSP12011892 ECSP12011892A (en) | 2009-11-13 | 2012-05-11 | COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY |
IL219769A IL219769A0 (en) | 2009-11-13 | 2012-05-13 | Drug combination with theromine and its use in therapy |
ZA2012/04247A ZA201204247B (en) | 2009-11-13 | 2012-06-11 | Drug combination with theobromine and its use in therapy |
US14/287,015 US9308211B2 (en) | 2009-06-16 | 2014-05-24 | Drug combinations and uses in treating a coughing condition |
US14/287,017 US10016437B2 (en) | 2009-06-16 | 2014-05-24 | Drug combinations and uses in treating a coughing condition |
US14/287,014 US9314465B2 (en) | 2009-06-16 | 2014-05-24 | Drug combinations and uses in treating a coughing condition |
US14/488,215 US20150005325A1 (en) | 2009-06-16 | 2014-09-16 | Drug Combinations and Uses in Treating a Coughing Condition |
US14/687,393 US20150216869A1 (en) | 2009-06-16 | 2015-04-15 | Drug Combinations and Uses in Treating a Coughing Condition |
US14/991,892 US20160120899A1 (en) | 2009-06-16 | 2016-01-08 | Drug Combinations and Uses in Treating a Coughing Condition |
US15/061,656 US9700561B2 (en) | 2009-06-16 | 2016-03-04 | Drug combinations and uses in treating a coughing condition |
US15/063,465 US9675618B2 (en) | 2009-06-16 | 2016-03-07 | Drug combinations and uses in treating a coughing condition |
US15/144,800 US20160271197A1 (en) | 2009-06-16 | 2016-05-02 | Drug Combinations and Uses in Treating a Coughing Condition |
US15/144,798 US20160271136A1 (en) | 2009-06-16 | 2016-05-02 | Drug Combinations and Uses in Treating a Coughing Condition |
US16/042,670 US10420812B2 (en) | 2009-06-16 | 2018-07-23 | Drug combinations and uses in treating a coughing condition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0919893.8 | 2009-11-13 | ||
GBGB0919893.8A GB0919893D0 (en) | 2009-11-13 | 2009-11-13 | Drug composition and its use in therapy |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/050997 Continuation-In-Part WO2010146394A1 (en) | 2009-06-16 | 2010-06-15 | Theobromine for the treatment of cough |
PCT/GB2010/051895 Continuation-In-Part WO2011058373A2 (en) | 2009-06-16 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/051895 Continuation-In-Part WO2011058373A2 (en) | 2009-06-16 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
PCT/GB2010/052085 Continuation-In-Part WO2011073646A1 (en) | 2009-06-16 | 2010-12-14 | Combination of theobromine with a decongestant and its use for the treatment of cough |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011058374A1 true WO2011058374A1 (en) | 2011-05-19 |
Family
ID=41509327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/051896 WO2011058374A1 (en) | 2009-06-16 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP2498776A1 (en) |
JP (2) | JP2013510842A (en) |
CN (1) | CN102740853B (en) |
AU (1) | AU2010317668C1 (en) |
BR (1) | BR112012011224A2 (en) |
CA (1) | CA2780704C (en) |
CO (1) | CO6551745A2 (en) |
EC (2) | ECSP12011892A (en) |
GB (1) | GB0919893D0 (en) |
IL (1) | IL219769A0 (en) |
MX (1) | MX2012005538A (en) |
NZ (1) | NZ599957A (en) |
PE (1) | PE20121472A1 (en) |
RU (1) | RU2587329C2 (en) |
SG (1) | SG10201407496SA (en) |
UA (1) | UA105940C2 (en) |
WO (1) | WO2011058374A1 (en) |
ZA (1) | ZA201204247B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703158B2 (en) | 2009-06-16 | 2014-04-22 | Biocopea Limited | Theobromine for the treatment of cough |
JP2014518252A (en) * | 2011-07-05 | 2014-07-28 | バイオコピア リミテッド | Combinations of drugs and use in the treatment of cough conditions |
US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989003213A1 (en) * | 1987-10-08 | 1989-04-20 | Andor Bilas | Mixture of substances for stabilyzing metabolism |
WO1995007103A1 (en) * | 1993-09-07 | 1995-03-16 | The Procter & Gamble Company | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
WO1998042322A2 (en) | 1997-03-26 | 1998-10-01 | Korbonits Dezso | Antitussive compositions |
WO2000030715A1 (en) * | 1998-11-25 | 2000-06-02 | Chinoin Gyógyszer És Vegyészeti | Composition containing an analgesic and a xanthine or a xanthine derivative |
CN1593451A (en) * | 2003-09-12 | 2005-03-16 | 杨喜鸿 | Externally applied medicine for promoting male erection |
WO2008002514A2 (en) * | 2006-06-26 | 2008-01-03 | Levine Brian M | Combination cough treatment compounds and method of treating common coughs |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608073B1 (en) * | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
AU2002356962C1 (en) * | 2001-12-12 | 2008-05-01 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
MXPA05009179A (en) * | 2003-02-28 | 2006-03-08 | Delex Therapeutics Inc | Opioid delivery system. |
JPWO2006064780A1 (en) * | 2004-12-14 | 2008-06-12 | 塩野義製薬株式会社 | Constipation treatment |
KR20080009994A (en) * | 2006-07-25 | 2008-01-30 | 안국약품 주식회사 | Compositions for treating of cough |
-
2009
- 2009-11-13 GB GBGB0919893.8A patent/GB0919893D0/en not_active Ceased
-
2010
- 2010-11-12 EP EP10778715A patent/EP2498776A1/en not_active Ceased
- 2010-11-12 CN CN201080051628.4A patent/CN102740853B/en not_active Expired - Fee Related
- 2010-11-12 CA CA2780704A patent/CA2780704C/en not_active Expired - Fee Related
- 2010-11-12 UA UAA201207163A patent/UA105940C2/en unknown
- 2010-11-12 JP JP2012538416A patent/JP2013510842A/en active Pending
- 2010-11-12 SG SG10201407496SA patent/SG10201407496SA/en unknown
- 2010-11-12 MX MX2012005538A patent/MX2012005538A/en unknown
- 2010-11-12 BR BR112012011224A patent/BR112012011224A2/en not_active IP Right Cessation
- 2010-11-12 AU AU2010317668A patent/AU2010317668C1/en not_active Ceased
- 2010-11-12 NZ NZ599957A patent/NZ599957A/en not_active IP Right Cessation
- 2010-11-12 PE PE2012000650A patent/PE20121472A1/en not_active Application Discontinuation
- 2010-11-12 WO PCT/GB2010/051896 patent/WO2011058374A1/en active Application Filing
- 2010-11-12 RU RU2012124063/15A patent/RU2587329C2/en not_active IP Right Cessation
-
2012
- 2012-05-11 CO CO12078022A patent/CO6551745A2/en not_active Application Discontinuation
- 2012-05-11 EC ECSP12011892 patent/ECSP12011892A/en unknown
- 2012-05-11 EC ECSP12011893 patent/ECSP12011893A/en unknown
- 2012-05-13 IL IL219769A patent/IL219769A0/en unknown
- 2012-06-11 ZA ZA2012/04247A patent/ZA201204247B/en unknown
-
2015
- 2015-12-04 JP JP2015237086A patent/JP2016041748A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989003213A1 (en) * | 1987-10-08 | 1989-04-20 | Andor Bilas | Mixture of substances for stabilyzing metabolism |
WO1995007103A1 (en) * | 1993-09-07 | 1995-03-16 | The Procter & Gamble Company | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
WO1998042322A2 (en) | 1997-03-26 | 1998-10-01 | Korbonits Dezso | Antitussive compositions |
WO2000030715A1 (en) * | 1998-11-25 | 2000-06-02 | Chinoin Gyógyszer És Vegyészeti | Composition containing an analgesic and a xanthine or a xanthine derivative |
CN1593451A (en) * | 2003-09-12 | 2005-03-16 | 杨喜鸿 | Externally applied medicine for promoting male erection |
WO2008002514A2 (en) * | 2006-06-26 | 2008-01-03 | Levine Brian M | Combination cough treatment compounds and method of treating common coughs |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Week 200573, Derwent World Patents Index; AN 2005-704785, XP002615349 * |
See also references of EP2498776A1 |
USMANI OMAR S ET AL: "Theobromine inhibits sensory nerve activation and cough", FASEB JOURNAL, vol. Faseb-Journal-Express, 17 November 2004 (2004-11-17), pages 1 - 16, XP009136788, ISSN: 0892-6638, [retrieved on 20041117], DOI: DOI:10.1096/FJ.04-1990FJE * |
USMENI ET AL., FASEB J. |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703158B2 (en) | 2009-06-16 | 2014-04-22 | Biocopea Limited | Theobromine for the treatment of cough |
US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US9675618B2 (en) | 2009-06-16 | 2017-06-13 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US9700561B2 (en) | 2009-06-16 | 2017-07-11 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
JP2014518252A (en) * | 2011-07-05 | 2014-07-28 | バイオコピア リミテッド | Combinations of drugs and use in the treatment of cough conditions |
Also Published As
Publication number | Publication date |
---|---|
ECSP12011892A (en) | 2012-09-28 |
CO6551745A2 (en) | 2012-10-31 |
EP2498776A1 (en) | 2012-09-19 |
RU2012124063A (en) | 2013-12-20 |
JP2013510842A (en) | 2013-03-28 |
AU2010317668B2 (en) | 2015-01-22 |
CN102740853A (en) | 2012-10-17 |
NZ599957A (en) | 2014-05-30 |
CN102740853B (en) | 2015-04-08 |
JP2016041748A (en) | 2016-03-31 |
MX2012005538A (en) | 2012-09-28 |
UA105940C2 (en) | 2014-07-10 |
IL219769A0 (en) | 2012-07-31 |
ECSP12011893A (en) | 2012-10-30 |
CA2780704A1 (en) | 2011-05-19 |
SG10201407496SA (en) | 2015-02-27 |
CA2780704C (en) | 2018-07-17 |
ZA201204247B (en) | 2013-02-27 |
BR112012011224A2 (en) | 2017-03-01 |
AU2010317668C1 (en) | 2016-02-11 |
AU2010317668A1 (en) | 2012-06-07 |
GB0919893D0 (en) | 2009-12-30 |
PE20121472A1 (en) | 2012-11-30 |
RU2587329C2 (en) | 2016-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6118919B2 (en) | Drug combination with theobromine and its use in therapy | |
AU2010332495C1 (en) | Therapeutic combinations of theobromine and an antihistamine | |
AU2010317668B2 (en) | Drug combination with theobromine and its use in therapy | |
CA2784214C (en) | Combination of theobromine with a decongestant and its use for the treatment of cough | |
AU2015201845B2 (en) | Drug combination with theobromine and its use in therapy | |
AU2015200654B2 (en) | Combination of theobromine with a decongestant and its use for the treatment of cough | |
AU2015201844B2 (en) | Therapeutic Combinations of Theobromine and an Antihistamine | |
AU2015200651B2 (en) | Theobromine in combination with an expectorant or a mucolytic for use in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080051628.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10778715 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2780704 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012538416 Country of ref document: JP Ref document number: 2010317668 Country of ref document: AU Ref document number: 12078022 Country of ref document: CO Ref document number: 000650-2012 Country of ref document: PE Ref document number: MX/A/2012/005538 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201002227 Country of ref document: TH Ref document number: 219769 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12012500955 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4528/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010317668 Country of ref document: AU Date of ref document: 20101112 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2010778715 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010778715 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201207163 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012124063 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012011224 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012011224 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120511 |